Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study

BMC Cancer

Jiawei Chen²  Xinhai Cui³  Hai Zhou²  Chao Qin²  Qiang Cao²  Xiaobing Ju²  Pu Li²  Hongzhou Cai²  Jian Zhu²  Xiaoxin Meng²  Meilin Wang¹  Zhengdong Zhang¹  Pengfei Shao²  Jie Li²  Changjun Yin² 

[1] Department of Molecular and Genetic Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China

[2] State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 300 Guangzhou Road, Nanjing 210029, China

[3] Department of Pediatric surgery, Qiluhospital Shandong University, Jinan, China

关键词: Apoptosis;    Survivin;    Genetic variation;    Prostate cancer;   

Others  :  1079634
DOI  :  10.1186/1471-2407-13-356

 received in 2012-03-06, accepted in 2013-06-24,  发布年份 2013

【 摘 要 】

Background

Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer and is considered as a new therapeutic target. We suppose that genetic variant rs9904341 in the 5′ UTR region of survivin gene may be associated with the development and progression of prostate cancer (PCa) in Chinese population.

Methods

TaqMan assay method was used to genotype the polymorphism in the hospital-based case–control analysis of 665 patients with PCa and 710 age-matched cancer-free controls. The genetic associations with the occurrence and progression of PCa were calculated by logistic regression.

Results

Our results indicated that compared with GG genotypes, there was a statistically significant increased risk of PCa associated with those with CC genotypes [odds ratios (ORs) = 1.57, 95%confidence intervals (CIs) = 1.17-2.13, P = 0.004]. Moreover, stratification analysis revealed that the association was more pronounced in subgroups of nondrinkers, nonsmokers and those without a family history of cancer (all P < 0.05). In addition, we observed that PSA ≥ 20 was more frequent in patients carrying GC/CC genotypes than in those with a wild type genotype.

Conclusion

The functional survivin rs9904341 genetic variant may have a substantial influence on the PCa susceptibility and evolution.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267(5203):1456-1462.
• [2]Hajra KM, Liu JR: Apoptosome dysfunction in human cancer. Apoptosis 2004, 9(6):691-704.
• [3]Li F, Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 1999, 344(Pt 2):305-311.
• [4]Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8):917-921.
• [5]Li F, Ling X: Survivin study: an update of “what is the next wave“? J Cell Physiol 2006, 208(3):476-486.
• [6]Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711):580-584.
• [7]Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001, 7(12):542-547.
• [8]Salvesen GS, Duckett CS: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 2002, 3(6):401-410.
• [9]Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004, 64(20):7183-7190.
• [10]Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997, 16(23):6914-6925.
• [11]Li F, Altieri DC: The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999, 59(13):3143-3151.
• [12]Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD: Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 2007, 204(7):1603-1611.
• [13]Jiang Y, de Bruin A, Caldas H, Fangusaro J, Hayes J, Conway EM, Robinson ML, Altura RA: Essential role for survivin in early brain development. J Neurosci 2005, 25(30):6962-6970.
• [14]Xing Z, Conway EM, Kang C, Winoto A: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004, 199(1):69-80.
• [15]Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, et al.: Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004, 199(3):399-410.
• [16]Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8(1):61-70.
• [17]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
• [18]McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007, 57(4):190-205.
• [19]Kanwar RK, Cheung CH, Chang JY, Kanwar JR: Recent advances in anti-survivin treatments for cancer . Curr Med Chem 2010, 17(15):1509-1515.
• [20]Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY: Investigations of survivin: the past, present and future . Front Biosci 2011, 16:952-961.
• [21]Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65(11):4881-4887.
• [22]Nomura T, Yamasaki M, Nomura Y, Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005, 14(4):993-997.
• [23]Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, et al.: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001, 95(2):92-95.
• [24]McEleny KR, Watson RW, Fitzpatrick JM: Defining a role for the inhibitors of apoptosis proteins in prostate cancer. Prostate Cancer Prostatic Dis 2001, 4(1):28-32.
• [25]Zhang M, Latham DE, Delaney MA, Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24(15):2474-2482.
• [26]McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM: Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002, 51(2):133-140.
• [27]Xing N, Qian J, Bostwick D, Bergstralh E, Young CY: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001, 48(1):7-15.
• [28]Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al.: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003, 9(13):4914-4925.
• [29]Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K: Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer . J Urol 2011, 185(4):1497-1503.
• [30]Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H: Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004, 171(5):1855-1860.
• [31]Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004, 100(4):751-757.
• [32]Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, et al.: Survivin is a potential mediator of prostate cancer metastasis . Int J Radiat Oncol Biol Phys 2010, 78(4):1095-1103.
• [33]Ma F, Zhang H, Zhai Y, Huang W, Zhao C, Ou S, Zhou H, Yuan W, Wang Z, Wang H, et al.: Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese . PLoS One 2011, 6(2):e16748.
• [34]Bayram S, Akkiz H, Bekar A, Akgollu E: The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population . Cancer Epidemiol 2011, 35(6):555-559.
• [35]Borges Bdo N, Burbano RR, Harada ML: Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population . Clin Exp Med 2010, 11(3):189-193.
• [36]Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Sato S, Mitobe Y, Narita S, Habuchi T: Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility . Int J Cancer 2011, 129(8):1872-1880.
• [37]Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B: Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India . Ann Surg Oncol 2010, 18(3):880-887.
• [38]Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, Yang K, Bai Y: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009, 135(10):1341-1349.
• [39]Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, Shen CH: Association between survivin gene promoter −31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009, 73(3):670-674.
• [40]Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N: Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009, 24(2):145-150.
• [41]Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, Dong H, Sun Q, Cong R, Chen G, et al.: The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009, 54(5):1021-1028.
• [42]Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE, et al.: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60(1):31-39.
• [43]Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, Veress G: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007, 60(3):303-306.
• [44]Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004, 23(9):527-537.
• [45]O'Neill AJ, Boran SA, O'Keane C, Coffey RN, Hegarty NJ, Hegarty P, Gaffney EF, Fitzpatrick JM, Watson RW: Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate 2001, 47(3):183-188.
• [46]Kyprianou N, King ED, Bradbury D, Rhee JG: bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997, 70(3):341-348.
• [47]Pan L, Peng XC, Leng F, Yuan QZ, Shan Y, Yu DD, Li ZY, Chen X, Xiao WJ, Wen Y, et al.: Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer . J Cancer Res Clin Oncol 2010, 137(1):19-28.
• [48]Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, Mahrampour E, Larijani B, Tavakkoly-Bazzaz J, Amoli MM: Association of Survivin Gene Polymorphism With Endometrial Cancer . Int J Gynecol Cancer 2012, 22(1):35-37.
• [49]Brouillette RM, Martin CK, Correa JB, Davis AB, Han H, Johnson WD, Foil HC, Hymel A, Keller JN: Memory for names test provides a useful confrontational naming task for aging and continuum of dementia. J Alzheimers Dis 2011, 23(4):665-671.
• [50]Hmeljak J, Erculj N, Dolzan V, Kern I, Cor A: BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients . J Cancer Res Clin Oncol 2011, 137(11):1641-1651.
• [51]Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H: Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010, 5(11):1748-1754.
• [52]Srivastava K, Srivastava A, Mittal B: Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 2011, 39(2):1509-1516.